National Systemic Anti-Cancer Therapy (SACT) consent forms – forms for melanoma regimens and generic immunotherapy form published

By BOPA Committee on 14 December 2016

The regimen-specific consent forms for melanoma and a generic form for immunotherapy have been published on the Cancer Research UK (CRUK) website.  There are 13 forms for melanoma:
 
  • Carboplatin
  • Cobimetinib-Vemurafenib
  • CVD (cisplatin-vinblastine-dacarbazine)
  • Dabrafenib
  • Dabrafenib-Trametinib
  • Dacarbazine
  • Ipilimumab
  • Ipilimumab-Nivolumab
  • Nivolumab
  • Pembrolizumab
  • Talimogene laherparepvec (Imlyglic®)
  • Temozolomide
  • Vemurafenib
 
Please visit www.cruk.org/sact_consent to view and download the forms.  Other forms, national guidance on consent for SACT, and further information is also available via www.cruk.org/sact_consent.
 
The National Chemotherapy Board published guidance on consent for SACT in July 2016 and recommends use of the regimen-specific forms in the UK.  The forms have been produced with support from CRUK.
 
Please do not hesitate to contact Rena Chauhan (Oncology Pharmacist – CRUK information lead, Guy’s and St. Thomas’ NHS Foundation Trust) if you have any queries: rena.chauhan@gstt.nhs.uk.
 
Rena Chauhan
14th December 2016
 
Close
Close
Close